Skip to main content
COGT
NASDAQ Life Sciences

Director-affiliated fund sells $127.4M in Cogent Biosciences stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$39.53
Mkt Cap
$6.011B
52W Low
$3.72
52W High
$43.73
52W Position info
963% above low
Off High info
9.6% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

COGT has more than doubled off its 52-week low of $3.72.

Summary

A director-affiliated fund, Fairmount Funds Management LLC, sold $127.4 million worth of Cogent Biosciences stock in a significant open market transaction.


Key Events · Ownership and Investor Activity · COGT

  • Significant Insider Sale

    Fairmount Funds Management LLC, an entity affiliated with a director, sold 3,500,000 shares of Cogent Biosciences common stock for a total value of $127,400,000.

  • Substantial Stake Reduction

    The sale represents a significant portion of the company's market capitalization and reduces the reporting owner's common stock holdings to 5,503,418 shares post-transaction.

  • Transaction Details

    The shares were sold at a price of $36.40 per share on January 22, 2026, which is below the current stock price of $39.53.


Analysis · COGT · Life Sciences

Fairmount Funds Management LLC, an entity affiliated with a director, executed a substantial open market sale of Cogent Biosciences stock totaling $127.4 million. This significant disposition, representing over 2% of the company's market capitalization, could signal a reduction in conviction from a key institutional investor and director-affiliated entity. The shares were sold at $36.40, below the current market price of $39.53. Investors should monitor for further insider activity or any related company announcements.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, COGT was trading at $39.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6B. The 52-week trading range was $3.72 to $43.73. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

COGT - Latest Insights

COGT
Nov 05, 2026, 4:28 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $29.21
Real-time Price: $26.79 info
Change: -$2.42 (-8%) info
Market Cap: $4.669B info
COGT
Nov 05, 2026, 4:18 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $29.21
Real-time Price: $26.79 info
Change: -$2.42 (-8%) info
Market Cap: $4.669B info
COGT
Sep 15, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $33.50
Real-time Price: $26.79 info
Change: -$6.71 (-20%) info
Market Cap: $4.669B info
COGT
Aug 10, 2026, 4:11 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $41.53
Real-time Price: $26.79 info
Change: -$14.74 (-35%) info
Market Cap: $4.669B info
COGT
Aug 10, 2026, 8:06 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $40.55
Real-time Price: $26.79 info
Change: -$13.76 (-34%) info
Market Cap: $4.669B info